Validation of molecular and immunological factors with predictive importance in lung cancer.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Lung Cancer

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.LUNGCAN.2004.07.978PMID 15552796
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

  2003cited by this paper
• Critical role of both p27KIP1and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

  2003cited by this paper
• The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

  2003cited by this paper
• Prognostic impact of matrix metalloproteinase‐9 in operable non‐small cell lung cancer

  2003cited by this paper
• Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications.

  2003cited by this paper
• Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancer

  2003cited by this paper
• Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.

  2002cited by this paper
• Prognostic significance of p27KIP1 expression in resected non–small cell lung cancers: Analysis in combination with expressions of p16INK4A, pRB, and p53

  2002cited by this paper
• The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

  2002cited by this paper
• Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.

  2002cited by this paper
• Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer.

  2002cited by this paper
• The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.

  2002cited by this paper
• Prognostic significance of cytokine modulation in non‐small cell lung cancer

  2002cited by this paper
• Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

  2002cited by this paper
• A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers.

  2002cited by this paper
• Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

  2002cited by this paper
• HER‐2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma

  2002cited by this paper
• Constitutive activation of met kinase in non‐small‐cell lung carcinomas correlates with anchorage‐independent cell survival

  2002cited by this paper
• Elevated Serum Levels of Interleukin-8 in Advanced Non-Small Cell Lung Cancer Patients: Relationship with Prognosis

  2002cited by this paper
• Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients.

  2002cited by this paper
• Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

  2002cited by this paper
• A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma

  2002cited by this paper
• Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.

  2001cited by this paper
• A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes

  2001cited by this paper
• Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.

  2001cited by this paper
• The intratumoral expression of vascular endothelial growth factor and interleukin‐8 associated with angiogenesis in nonsmall cell lung carcinoma patients

  2001cited by this paper
• Vascular Endothelial Growth Factor Expression in Stage I Non-Small Cell Lung Cancer Correlates With Neoangiogenesis and a Poor Prognosis

  2001cited by this paper
• Neue Aspekte der Immunbiologie des nichtkleinzelligen Bronchialkarzinoms

  2001cited by this paper
• High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients.

  2001cited by this paper
• Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer.

  2001cited by this paper
• [Immunobiology of the non-small-cell lung carcinoma: new aspects].

  2001cited by this paper
• Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.

  2001cited by this paper
• Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer.

  2001cited by this paper
• p53 and K-ras mutations in lung cancers from former and never-smoking women.

  2001cited by this paper
• Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas.

  2001cited by this paper
• Long-term survival in small cell lung cancer patients is correlated with high interleukin-2 secretion at diagnosis

  2000cited by this paper
• Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients.

  2000cited by this paper
• Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.

  2000cited by this paper
• Overexpression of Matrix Metalloproteinase 2 Predicts Unfavorable Outcome in Early-Stage Non-Small Cell Lung Cancer 1

  2000cited by this paper
• Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.

  2000cited by this paper
• The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.

  2000cited by this paper
• Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer.

  2000cited by this paper
• Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

  2000cited by this paper
• A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.

  2000cited by this paper
• Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer.

  2000cited by this paper
• K-ras gene mutations in non-small cell lung cancer in Japanese.

  2000cited by this paper
• Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.

  2000cited by this paper
• Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.

  2000cited by this paper
• Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer.

  2000cited by this paper
• Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells

  2000cited by this paper
• Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.

  1999cited by this paper
• Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome

  1999cited by this paper
• Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer

  1999cited by this paper
• Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.

  1999cited by this paper
• p53 mutations predict non-small cell lung carcinoma response to radiotherapy.

  1999cited by this paper
• Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.

  1999cited by this paper
• Expression of retinoid receptor genes and proteins in non-small-cell lung cancer.

  1999cited by this paper
• Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention.

  1999cited by this paper
• Molecular epidemiology of human cancer risk: gene–environment interactions and p53 mutation spectrum in human lung cancer

  1999cited by this paper
• Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

  1999cited by this paper
• Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer.

  1999cited by this paper
• Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers.

  1999cited by this paper
• K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

  1999cited by this paper
• Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras.

  1999cited by this paper
• The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.

  1999cited by this paper
• Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production.

  1998cited by this paper
• In vivo influence of p53 status on proliferation and chemoradiosensitivity in non-small-cell lung cancer

  1998cited by this paper
• Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.

  1998cited by this paper
• Progress in understanding the molecular pathogenesis of human lung cancer.

  1998cited by this paper
• Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

  1998cited by this paper
• CD4 lymphocyte deficiency and non-Hodgkin's lymphoma in the antiphospholipid syndrome.

  1998cited by this paper
• Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.

  1998cited by this paper
• Expression of interleukin-8 correlates with vascularity in human gastric carcinomas.

  1998cited by this paper
• Non-small cell lung cancer: clinical value of new biological predictors

  1997cited by this paper
• Bcl2 is the guardian of microtubule integrity.

  1997cited by this paper
• Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.

  1997cited by this paper
• Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

  1997cited by this paper
• Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression.

  1997cited by this paper
• Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development.

  1997cited by this paper
• Decrease of interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer.

  1997cited by this paper
• An Information-Intensive Approach to the Molecular Pharmacology of Cancer

  1997cited by this paper
• Altered retinoblastoma protein expression in nonsmall cell lung cancer

  1997cited by this paper
• Non-small cell lung cancer: clinical value of new biological predictors.

  1997cited by this paper
• Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.

  1997cited by this paper
• Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications.

  1997cited by this paper
• Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.

  1997cited by this paper
• Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines.

  1996cited by this paper
• Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer.

  1996cited by this paper
• Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers.

  1996cited by this paper
• Intragenic mutations of the p16INK4, p15INK4B and p18 genes in primary non‐small‐cell lung cancers

  1996cited by this paper
• Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance

  1996cited by this paper
• Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer.

  1996cited by this paper
• Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.

  1996cited by this paper
• Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.

  1996cited by this paper
• Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway.

  1996cited by this paper
• Rb and p16INK4a expression in resected non-small cell lung tumors.

  1996cited by this paper
• Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production.

  1996cited by this paper
• Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial cells.

  1995cited by this paper
• Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers

  1995cited by this paper
• In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.

  1995cited by this paper

• Reduction of Serum Cytokeratin-3A9 is Associated with Chemotherapeutic Response in Patients with Non-Small Cell Lung Cancer.

  2015cites this paper
• The clinical value of new tumor biomarker cytokeratin 2G2 detection in non-small cell lung cancer patients.

  2013cites this paper
• Molecular markers for incidence, prognosis, and response to therapy.

  2012cites this paper
• VEGF and IL-18 in induced sputum of lung cancer patients.

  2011cites this paper
• Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response

  2011cites this paper
• Experimental and Molecular Pathology

  2009cites this paper
• Platelet linoleic acid is a potential biomarker of advanced non-small cell lung cancer.

  2009cites this paper
• Erythrocyte and Platelet Phospholipid Fatty Acids as Markers of Advanced Non-Small Cell Lung Cancer: Comparison with Serum Levels of Sialic Acid, TPS and Cyfra 21-1

  2008cites this paper
• Impaired ̇ chain expression and IFN-Á production in peripheral blood T and NK cells of patients with advanced lung cancer

  2008cites this paper
• 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.

  2007cites this paper
• Genetic risk profiles for cancer susceptibility and therapy response.

  2007cites this paper
• p53 and HER2/neu Expression in Relation to Chemotherapy Response in Patients with Non-Small Cell Lung Cancer

  2006cites this paper
• Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.

  2006cites this paper
• Cytogenetic and molecular aspects of lung cancer.

  2006cites this paper
• Biomarkers in Disease Diagnosis and Treatment

  2006cites this paper
• BIOMARKERS IN DISEASE DIAGNOSIS AND TREATMENT of Biomarkers to Improve Patient Care

  2006cites this paper
• Pretreatment Serum Levels of Cytokines and Cytokine Receptors in Patients with Non-Small Cell Lung Cancer, and Correlations with Clinicopathological Features and Prognosis

  2006cites this paper
• Properties of blood proteins and peptides: application to multi-dimensional liquid chromatography mass spectrometry

  2005cites this paper
• Mechanisms of lung cancer

  2005cites this paper
• TRANSPORT TRANSENDOTHÉLIAL DE GÈNES : ÉTUDES DYNAMIQUES DU PASSAGE SÉLECTIF DE POLYPLEXES AU TRAVERS DE L'ENDOTHÉLIUM VASCULAIRE PULMONAIRE.

  2005cites this paper
• Molecular oncology--perspectives in lung cancer.

  2004cites this paper